<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Determination That NORFLEX (Orphenadrine Citrate) Injection, 30 Milligrams/Milliliter, and NORFLEX (Orphenadrine Citrate) Extended-Release Tablet, 100 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Determination That NORFLEX (Orphenadrine Citrate) Injection, 30 Milligrams/Milliliter, and NORFLEX (Orphenadrine Citrate) Extended-Release Tablet, 100 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness</h1>
    <p class="timestamp">Published: 2022-12-08 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA, Agency, or we) has determined that NORFLEX (orphenadrine citrate) Injection, 30 milligrams (mg)/milliliter (mL), and NORFLEX (orphenadrine citrate) Extended- Release Tablet, 100 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs ...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2022-26663</p>
    <p><strong>Publication Date:</strong> 2022-12-08</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/12/08/2022-26663/determination-that-norflex-orphenadrine-citrate-injection-30-milligramsmilliliter-and-norflex">https://www.federalregister.gov/documents/2022/12/08/2022-26663/determination-that-norflex-orphenadrine-citrate-injection-30-milligramsmilliliter-and-norflex</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-26663</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
